A nasal spray which is used by those with treatment-resistant depression has not been recommended for use by NICE due to uncertainties over its clinical and cost-effectiveness.
Nasal Spray
Esketamine, (which is also known as Spravato and is made my Jenssen) with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibito (SNRI) is not recommended within its marketing authorization, for adults with treatment-resistant depression that haven’t responded to at least two different antidepressants.
Please register or login to comment!
Register now Login